You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

CLINICAL TRIALS PROFILE FOR APABETALONE

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for apabetalone

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00768274 ↗	Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol	Completed	Resverlogix Corp	Phase 1/Phase 2	The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.
NCT01058018 ↗	Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease	Completed	Resverlogix Corp	Phase 2	The purpose of this study is to investigate dose range, safety and efficacy of RVX000222 in subjects with stable coronary artery disease.
NCT02586155 ↗	Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD	Completed	ICON plc	Phase 3	The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major adverse cardiovascular events.
NCT02586155 ↗	Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD	Completed	Medidata Solutions	Phase 3	The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major adverse cardiovascular events.
NCT02586155 ↗	Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD	Completed	PPD	Phase 3	The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major adverse cardiovascular events.
NCT02586155 ↗	Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD	Completed	Resverlogix Corp	Phase 3	The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major adverse cardiovascular events.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for apabetalone

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Coronary Artery Disease	2
Pulmonary Arterial Hypertension	2
Atherosclerosis	2
COVID-19 Infection	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Coronary Disease	2
Coronary Artery Disease	2
Pulmonary Arterial Hypertension	2
Hypertension	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for apabetalone

Trials by Country

Map
Table

Trials by Country
Location	Trials
Canada	6
United States	3
Argentina	1
Bulgaria	1
Hungary	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
California	2
Texas	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for apabetalone

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	2
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	3
Unknown status	2
Active, not recruiting	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for apabetalone

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Resverlogix Corp	8
Medidata Solutions	1
PPD	1
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	11
Other	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.